{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.1444.5.226",
  "meta" : {
    "versionId" : "12",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueContactDetail" : {
        "name" : "American Society of Clinical Oncology Author"
      }
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2023-06-23"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2021-03-20"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.226",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.1444.5.226"
    }
  ],
  "version" : "20210320",
  "name" : "ImmunotherapyAdministration",
  "title" : "Immunotherapy Administration",
  "status" : "active",
  "experimental" : false,
  "date" : "2022-03-03T18:46:01-05:00",
  "publisher" : "American Society of Clinical Oncology Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: The purpose of this value set is to represent concepts for the procedure of immunotherapy administration.),(Data Element Scope: This value set may use a model element related to Procedure.),(Inclusion Criteria: Includes concepts that represent a procedure for immunotherapy administration.),(Exclusion Criteria: No exclusions.)",
  "compose" : {
    "include" : [
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.177"
        ]
      },
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.175"
        ]
      },
      {
        "valueSet" : [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.174"
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:fa8a4dbe-719c-40ab-8a7a-5f7912f2d150",
    "timestamp" : "2024-11-09T00:53:32-05:00",
    "total" : 20,
    "contains" : [
      {
        "system" : "http://snomed.info/sct",
        "version" : "http://snomed.info/sct/731000124108/version/20240901",
        "code" : "180223008",
        "display" : "Intravenous immunotherapy (procedure)"
      },
      {
        "system" : "http://snomed.info/sct",
        "version" : "http://snomed.info/sct/731000124108/version/20240901",
        "code" : "180244008",
        "display" : "Intramuscular immunotherapy (procedure)"
      },
      {
        "system" : "http://snomed.info/sct",
        "version" : "http://snomed.info/sct/731000124108/version/20240901",
        "code" : "180256009",
        "display" : "Subcutaneous immunotherapy (procedure)"
      },
      {
        "system" : "http://snomed.info/sct",
        "version" : "http://snomed.info/sct/731000124108/version/20240901",
        "code" : "589631000119102",
        "display" : "Intravenous radioimmunotherapy using monoclonal antibodies (procedure)"
      },
      {
        "system" : "http://snomed.info/sct",
        "version" : "http://snomed.info/sct/731000124108/version/20240901",
        "code" : "60827006",
        "display" : "Lymphokine activated killer cell therapy (procedure)"
      },
      {
        "system" : "http://snomed.info/sct",
        "version" : "http://snomed.info/sct/731000124108/version/20240901",
        "code" : "72255009",
        "display" : "Interleukin-2 therapy (procedure)"
      },
      {
        "system" : "http://snomed.info/sct",
        "version" : "http://snomed.info/sct/731000124108/version/20240901",
        "code" : "76334006",
        "display" : "Immunotherapy (procedure)"
      },
      {
        "system" : "http://snomed.info/sct",
        "version" : "http://snomed.info/sct/731000124108/version/20240901",
        "code" : "84501003",
        "display" : "Cytokine therapy (procedure)"
      },
      {
        "system" : "http://snomed.info/sct",
        "version" : "http://snomed.info/sct/731000124108/version/20240901",
        "code" : "870387009",
        "display" : "Immune checkpoint inhibitor therapy (procedure)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "96365",
        "display" : "Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "96366",
        "display" : "Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "96372",
        "display" : "Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "96374",
        "display" : "Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "96401",
        "display" : "Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "96409",
        "display" : "Chemotherapy administration; intravenous, push technique, single or initial substance/drug"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "96413",
        "display" : "Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "96415",
        "display" : "Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2025",
        "code" : "96416",
        "display" : "Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2024",
        "code" : "Q2041",
        "display" : "Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version" : "2024",
        "code" : "Q2042",
        "display" : "Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"
      }
    ]
  }
}
